The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial

Koshikawa, Yosuke; Takekita, Yoshiteru; Kato, Masaki; Sakai, Shiho; Onohara, A.; Sunada, Naotaka; Nishida, Keiichiro; Yoshimura, Masafumi; Fabbri, Chiara; Serretti, Alessandro; Kinoshita, Toshihiko

doi:10.1159/000442209

Cited by 23 publications

(24 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A 6-month, open-label, randomized, controlled pilot study compared the effects of risperidone long-acting injection and paliperidone palmitate on non-acute-phase social functioning in patients with schizophrenia [ 132 ]. Assessments at baseline and 6 months included the SFS (primary outcome), University of California San Diego Performance-Based Skills Assessment Brief (UPSA-B), Social Emotional Cognition Task (SECT), PANSS, and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) [ 132 ]. Paliperidone palmitate was significantly more effective than risperidone long-acting injection on change from baseline in SFS total score, and the SFS competence and performance subscales scores [ 132 ].…”

Section: Interventions Targeting Social Cognition In Schizophreniamentioning

confidence: 99%

“…Assessments at baseline and 6 months included the SFS (primary outcome), University of California San Diego Performance-Based Skills Assessment Brief (UPSA-B), Social Emotional Cognition Task (SECT), PANSS, and Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS) [ 132 ]. Paliperidone palmitate was significantly more effective than risperidone long-acting injection on change from baseline in SFS total score, and the SFS competence and performance subscales scores [ 132 ]. The treatment groups did not differ significantly on change from baseline in UPSA-B, SECT, PANSS, and DIEPSS [ 132 ].…”

Section: Interventions Targeting Social Cognition In Schizophreniamentioning

confidence: 99%

See 1 more Smart Citation

The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia

2018

View full text Add to dashboard Cite

Social cognition has become recognized as an important driver of functional outcomes and overall recovery in patients with schizophrenia, mediating the relationship between neurocognition and social functioning. Since antipsychotic therapy targeting remission of clinical symptoms has been shown to have a limited impact on social cognition, there has been an increasing drive to develop therapeutic strategies to specifically improve social cognition in schizophrenia. We sought to review current evidence relating to social cognition in schizophrenia and its clinical implications, including interventions designed to target the core domains of social cognition (emotion processing, theory of mind, attributional bias, and social perception) as a means of improving functional outcomes and thereby increasing the likelihood of recovery. Relevant articles were identified by conducting a literature search in PubMed using the search terms “schizophrenia” AND “cognition” AND “social functioning,” limited to Title/Abstract, over a time period of the past 10 years. Current evidence demonstrates that schizophrenia is associated with impairments in all four core domains of social cognition, during the pre-first-episode, first-episode, early, and chronic phases of the disease, and that such impairments are important determinants of functional outcome. Interventions targeting the four core domains of social cognition comprise psychosocial approaches (social cognition training programs) and pharmacological therapies. Social cognition training programs targeting multiple and specific core domains of social cognition have shown promise in improving social cognition skills, which, in some cases, has translated into improvements in functional outcomes. Use of some psychosocial interventions has additionally resulted in improvements in clinical symptoms and/or quality of life. Pharmacological therapies, including oxytocin and certain antipsychotics, have yielded more mixed results, due in part to the confounding impact of factors including variation in receptor genetics, bioavailability, pharmacokinetics, and drug–drug interactions, and inconsistencies between study designs and medication dosages. Additional research is required to advance our understanding of the role of social cognition in schizophrenia, and to further establish the utility of targeted interventions in this setting.

show abstract

Section: Interventions Targeting Social Cognition In Schizophreniamentioning

confidence: 99%

Section: Interventions Targeting Social Cognition In Schizophreniamentioning

confidence: 99%

The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia

2018

View full text Add to dashboard Cite

show abstract

“…The PP-treated patients showed a greater degree of total social functioning, independent life competence, and performance as compared to the RLAI group. 37 In the same sample, effects of PP-1M and RLAI on cognitive functions were compared. The results suggested that PP might improve attention and processing speed more than RLAI.…”

Section: Comparative Randomized Controlled Trialsmentioning

confidence: 99%

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Emsley¹,

Kilian²

2018

NDT

View full text Add to dashboard Cite

The course of schizophrenia is characterized by multiple relapses, incomplete remission of symptoms, enduring cognitive deficits, and social and occupational functional impairments. Nonadherence to antipsychotic medication is a major determinant of this poor outcome. Long-acting injectable antipsychotics were developed specifically to address the nonadherence problem and are increasingly considered as an early treatment option, in an attempt to prevent accruing morbidity. This review focuses on paliperidone palmitate, the long-acting injectable (LAI) formulation of paliperidone. After considering the pharmacology of paliperidone palmitate, we review the randomized controlled trials, as well as pertinent observational, pragmatic studies for paliperidone once-monthly injections in schizophrenia. Finally, we review the recently introduced 3-monthly formulation of paliperidone palmitate. Taken together, the studies indicate that paliperidone palmitate (PP) has good efficacy compared with placebo and comparable with other antipsychotics including risperidone. The tolerability profile of PP is similar to that of risperidone, with the most important side effects being prolactin elevation, weight gain, and extrapyramidal symptoms. Advantages of PP include the extensive research database and clinical experience with paliperidone and its parent compound risperidone, the availability of different LAI formulations (once-monthly, 3-monthly, and perhaps even longer acting formulations in future), and the novel dose initiation procedure that provides rapid onset of action without the need for oral antipsychotic supplementation.

show abstract

“…Some researchers have proposed that social cognition deficits may be a schizophrenia vulnerability marker [ 12 ] affecting real-life functioning in people [ 13 ]. To date, no differences have been found in social emotion cognition task performance after treatment with LAI-SGAs in patients with schizophrenia [ 14 ]. However, the lack of empirical data on this relationship did not allow for definitive conclusions to be made.…”

Section: Introductionmentioning

confidence: 99%

Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Corigliano

Comparelli

Mancinelli

et al. 2018

Schizophrenia Research and Treatment

View full text Add to dashboard Cite

Long-acting injectable second-generation antipsychotics (LAI-SGA) are typically used to maintain treatment adherence in patients with chronic schizophrenia. Recent research suggests that they may also provide an effective treatment strategy for patients with early-phase disease. The aim of this study is to evaluate clinical and psychosocial outcomes among recent and long-term diagnosed schizophrenia outpatients treated with LAI-SGA during a follow-up period of 12 months. Stable schizophrenia patients receiving LAI-SGA with 5 or less years of illness duration (n = 10) were compared to those with more than 5 years of illness duration (n = 15). Clinical data was assessed through the Positive and Negative Syndrome Scale (PANSS), the Global Assessment of Functioning (GAF), the Columbia Suicide Severity Rating Scale (C-SSRS), the Recovery Style Questionnaire (RSQ), and the Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT) Managing Emotion branch. Recently diagnosed patients showed greater improvement versus patients diagnosed for more than 5 years in adjusted mean GAF score, in PANSS factor score for negative and depressive symptoms, and in severity and intensity of suicidal ideation. Our preliminary findings support the hypothesis that LAI-SGA may influence the course of the illness if administered at the early phase of the illness. However, replicate studies are needed, possibly with larger samples.

show abstract

The Comparative Effects of Risperidone Long-Acting Injection and Paliperidone Palmitate on Social Functioning in Schizophrenia: A 6-Month, Open-Label, Randomized Controlled Pilot Trial

Cited by 23 publications

References 40 publications

The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia

The Importance of Social Cognition in Improving Functional Outcomes in Schizophrenia

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review

Long-Acting Injectable Second-Generation Antipsychotics Improve Negative Symptoms and Suicidal Ideation in Recent Diagnosed Schizophrenia Patients: A 1-Year Follow-up Pilot Study

Contact Info

Product

Resources

About